Sector & Market
Spyre Therapeutics Director Sells $2.4M Stock
Director Jeffrey W. Albers sold 23,000 shares for approximately $2.4 million on August 7, 2026 under a Rule 10b5‑1 trading plan.
Sale comprised three tranches: 5,000 shares directly at $104.47 avg, an
